D. Boral Capital downgraded VolitionRx (VNRX) to Hold from Buy without a price target citing the company’s 1-for-20 reverse stock split, effective April 28. Reverse splits are typically a negative for shareholders because they often signal financial stress, listing pressure, and limited strategic alternatives rather than underlying business strength, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNRX:
- VolitionRx Sets One-for-Twenty Reverse Stock Split
- VolitionRx Earnings Call: Breakthroughs Amid Funding Strain
- VolitionRx: Robust Revenue Growth and Promising Capture-Seq Data Support Buy Rating Despite Dilution-Driven Target Cut
- VolitionRx price target lowered to $1 from $1.50 at H.C. Wainwright
- VolitionRx Shareholders Approve Stock Issuance and Reverse Split